Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : FDA Authorizes New Saliva Sample Collection Method for High-Throughput, Automated COVID-19 Testing System

10/19/2021 | 07:14am EST

CARLSBAD, Calif. - Thermo Fisher Scientific, the world leader in serving science, announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) to run COVID-19 tests from saliva samples collected with the Spectrum Solutions SpectrumDNA SDNA-1000 collection device on the Amplitude Solution.

SDNA saliva collection devices are self-contained systems that provide sample consistency and long-term stability while protecting DNA and RNA transcripts post-collection to help ensure accurate test results with only two milliliters of saliva. The Amplitude Solution gives laboratories the ability to scale COVID-19 PCR testing and process up to 8,000 samples in a single day.

'With the increase of COVID-19 cases due to more transmissible variants such as the Delta variant, routine testing for SARS-CoV-2 remains an effective strategy to curb the pandemic,' said Manoj Gandhi, senior medical director of genetic testing solutions, Thermo Fisher Scientific. 'By enabling labs and public health officials with additional flexibility in sample collection on a high-throughput system, we are improving their ability to meet the increased demand which helps to monitor the spread of COVID-19 and, eventually, save lives.'

The Amplitude Solution is a molecular diagnostic system that empowers clinical labs to expand testing capacity with minimal hands-on time, equipment and staffing. Its high-throughput capabilities can be flexed to address testing needs for companies, schools, universities and communities to help them return to pre-pandemic life. The kit's multi-gene target design and updated interpretive software is also designed to help labs detect SARS-CoV-2 variants.

For more information on the Amplitude platform, please visit: https://www.thermofisher.com/amplitude

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Contact:

Media

Mauricio Minotta

Director

Public Relations

Phone: +1 760-929-2456

E-mail: mauricio.minotta@thermofisher.com

Ariane Lovell

FINN Partners

Phone: +1 646-307-6317

E-mail: ariane.lovell@finnpartners.com

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about THERMO FISHER SCIENTIFIC
11/22Biocept Launches Combined COVID-19, Influenza Test; COVID-19 Test Developed With Aegea ..
MT
11/18THERMO FISHER SCIENTIFIC INC. : Entry into a Material Definitive Agreement, Regulation FD ..
AQ
11/18Thermo Fisher Scientific Announces Redemption of Senior Notes
PR
11/18Thermo Fisher Scientific Inc. Announces Redemption of Senior Notes
CI
11/15Thermo Fisher Scientific Selects Mebane, N.C. as Site for New Manufacturing Facility
AQ
11/15Cellenion Announces Co-Marketing Agreement for Single Cell Mass Spectrometry-Based Prot..
AQ
11/15Cellenion Announces Co-Marketing Agreement for Single Cell Mass Spectrometry-Based Prot..
CI
11/12Thermo Fisher Scientific Selects Mebane, N.C. as Site for New Manufacturing Facility
CI
11/09Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes
PR
11/09Thermo Fisher Scientific Inc. announces New IVD System Enables Assay Developers and Cli..
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 37 181 M - -
Net income 2021 7 605 M - -
Net Debt 2021 25 683 M - -
P/E ratio 2021 33,6x
Yield 2021 0,15%
Capitalization 252 B 252 B -
EV / Sales 2021 7,46x
EV / Sales 2022 6,71x
Nbr of Employees 80 000
Free-Float 89,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 638,74 $
Average target price 668,10 $
Spread / Average Target 4,60%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors